Get the Daily Brief
Latest Biotech News
AI drug-design startup Basecamp lands major funding for in vivo cell therapies
Basecamp Research raised $140 million in an oversubscribed Series C to train its next-generation EDEN foundation models and apply them to in vivo cell therapies across disease areas, the company...
Immunovant stops Phase 2 IMVT-1402 program after cutaneous lupus failure
Immunovant discontinued IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus after a Phase 2 setback, the company said. The decision closes one pathway for the anti-FcRn antibody approach and...
Novartis accelerates radioligand therapy pipeline via $900M Boomray licensing
Novartis agreed to a potential $900 million deal to secure exclusive global rights to a preclinical radioligand therapy asset from Boomray Pharmaceuticals, the companies said. The move is...
Telix and ITM to merge to scale radiopharmaceutical manufacturing and supply
Telix agreed to acquire Isotope Technologies Munich (ITM) in a consolidation move aimed at expanding radiopharmaceutical manufacturing scale and isotope supply control. The deal structure combines...
Amgen posts Phase 3 success in Sjögren’s with dazodalibep after Horizon acquisition
Amgen reported preliminary success for dazodalibep, its Horizon Therapeutics-acquired fusion protein, in a Phase 3 trial for Sjögren’s disease. The company said the candidate met the primary...
Adagene wins China IND clearance for ADG-138 HER2×CD3 bispecific T-cell engager
Adagene obtained IND clearance from China’s NMPA for ADG-138, a double-masked HER2×CD3 bispecific T-cell engager intended for advanced solid tumors. The company said it plans to start a...
Boehringer expands Variant Bio deal into cardiovascular applications
Boehringer Ingelheim expanded its collaboration with Variant Bio by adding cardiovascular disease coverage, increasing the deal value by $250 million. The update signals continued interest in...
FDA IND cleared for Systimmune bispecific SI-B037 targeting immunosuppression
Systimmune received IND clearance from the FDA for SI-B037, a bispecific antibody designed to target immunosuppression and other synergistic mechanisms, the company said. The clearance enables the...
Genetic and manufacturing oversight: MHRA warns eHR noncompliance can derail UK clinical trials
The UK’s MHRA warned that inadequate electronic health record (eHR) systems are undermining clinical trial feasibility in the NHS, potentially leading to site rejection during sponsor site...
Regulatory acceleration and trial infrastructure
The U.S. FDA rolled out a pilot program designed to speed up early-stage development by pairing drug sponsors with prequalified research institutions. The effort aims to reduce delays between IND...
Kidney disease drug wins and race for faster approvals
Roche reported interim success in a Phase 3 kidney disease study for enicepatide (previously CT-388), strengthening expectations for a path toward accelerated review. The update comes as companies...
Big pharma licensing deals reshape oncology target discovery
Boehringer Ingelheim extended its RNA splicing collaboration with Envisagenics in a deal that could total more than $1 billion. Boehringer will apply Envisagenics’ SpliceCore platform to validate...
AI drug design funding accelerates in vivo reprogramming ambitions
Basecamp Research completed an oversubscribed $140 million Series C financing to advance EDEN foundation models for AI-designed in vivo cell therapies. The company plans to train next-generation...
Rare disease and gene therapy momentum in ophthalmology
Beacon Therapeutics reported a Phase 3 success for laruparetigene zovaparvovec (laru-zova) in X-linked retinitis pigmentosa. The company said the treatment met its primary endpoint in the VISTA...
Cell and organoid engineering pushes oncology translation
BrainStorm Therapeutics, a human organoid-and-AI CNS discovery company, won a Seed-Stage Start-Up Stadium award for its use of patient-derived brain organoids to generate translational biological...
Gene therapy and gene editing tools move toward earlier feasibility
A proof-of-concept study reported CRISPR base editors correcting Artemis mutations outside the body as a potential route for ART-SCID (Artemis-deficient severe combined immunodeficiency). The work...
Immunology and oncology: targeted mechanisms and emerging therapeutics
Regcell raised $66 million, including Japanese government support, to advance its regulatory T-cell platform toward clinic testing. The company plans to convert disease-driving immune cells into...
Radiopharma consolidation and manufacturing scale-up
Telix agreed to acquire ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, aiming to strengthen isotope supply and manufacturing capacity as radiopharmaceutical demand rises....
Clinical and late-stage autoimmune development signals
Amgen reported preliminary Phase 3 success for dazodalibep in Sjögren’s disease, setting up an FDA review that could potentially make it the first therapy for a condition with no approved drugs....
Kidney disease: Roche and Vertex advance late-stage programs toward approval
Roche reported interim Phase 3 success for sefaxersen, setting up a potential accelerated-approval path in a crowded kidney-disease market as competitors expand their chronic-care portfolios. The...